S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
Log in

NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News

$7.21
-0.05 (-0.69 %)
(As of 01/28/2020 02:12 PM ET)
Today's Range
$7.13
Now: $7.21
$7.71
50-Day Range
$4.52
MA: $6.99
$9.21
52-Week Range
$4.45
Now: $7.21
$11.93
Volume64,556 shs
Average Volume307,462 shs
Market Capitalization$305.99 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.05 million
Book Value$2.34 per share

Profitability

Net Income$-62,280,000.00
Net Margins-3,115.38%

Miscellaneous

Employees76
Market Cap$305.99 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.


Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.01. The firm earned $0.56 million during the quarter, compared to the consensus estimate of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. View Syros Pharmaceuticals' Earnings History.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Syros Pharmaceuticals.

What price target have analysts set for SYRS?

7 analysts have issued 1-year price objectives for Syros Pharmaceuticals' stock. Their forecasts range from $9.00 to $18.00. On average, they expect Syros Pharmaceuticals' stock price to reach $13.83 in the next twelve months. This suggests a possible upside of 91.1% from the stock's current price. View Analyst Price Targets for Syros Pharmaceuticals.

What is the consensus analysts' recommendation for Syros Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syros Pharmaceuticals.

Has Syros Pharmaceuticals been receiving favorable news coverage?

Press coverage about SYRS stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Syros Pharmaceuticals earned a coverage optimism score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the company's share price in the near future. View News Stories for Syros Pharmaceuticals.

Are investors shorting Syros Pharmaceuticals?

Syros Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totalling 2,340,000 shares, an increase of 30.0% from the December 31st total of 1,800,000 shares. Based on an average trading volume of 479,200 shares, the days-to-cover ratio is currently 4.9 days. Approximately 7.6% of the company's shares are short sold. View Syros Pharmaceuticals' Current Options Chain.

Who are some of Syros Pharmaceuticals' key competitors?

What other stocks do shareholders of Syros Pharmaceuticals own?

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the folowing people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)
  • Dr. David A. Roth, Chief Medical Officer (Age 56)
  • Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)
  • Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Syros Pharmaceuticals' major shareholders?

Syros Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.07%). Company insiders that own Syros Pharmaceuticals stock include Jeremy P Springhorn, Richard A Young, Srinivas Akkaraju and Venture Fund Vii LP Arch. View Institutional Ownership Trends for Syros Pharmaceuticals.

Which institutional investors are buying Syros Pharmaceuticals stock?

SYRS stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn and Srinivas Akkaraju. View Insider Buying and Selling for Syros Pharmaceuticals.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $7.24.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $307.27 million and generates $2.05 million in revenue each year. The company earns $-62,280,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe.View Additional Information About Syros Pharmaceuticals.

What is Syros Pharmaceuticals' official website?

The official website for Syros Pharmaceuticals is http://www.syros.com/.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]


MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  589
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel